General Catalyst is a global, multi-stage investment firm with major hubs across the US and Europe, investing from seed through growth across technology and healthcare. The firm combines traditional venture capital with company creation and ecosystem-building, positioning itself as both an investor and an active partner in shaping large-scale markets.

A defining element of its strategy is the “Health Assurance” thesis, which focuses on transforming healthcare from reactive treatment to proactive, technology-enabled systems. General Catalyst operates beyond pure capital deployment, working with health systems, governments, and operators to build and scale integrated care models. Its Creation platform further extends this approach by incubating and launching companies internally.

For neurotechnology, General Catalyst is most relevant for businesses positioned at the intersection of healthcare delivery, AI, diagnostics, or digital clinical infrastructure, rather than purely device-driven innovation. It is particularly well suited to companies with the potential to scale into system-level platforms or reshape care pathways, where its ecosystem approach and operational involvement can create outsized impact.